Rafferty Asset Management
AMLX icon

Rafferty Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Rafferty Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,673
Closed -$213K – 1062
2025
Q4 		$213K Buy
+17,673
New +$240K ﹤0.01% 1089
2024
Q2 		– Sell
-53,201
Closed -$151K – 1170
2024
Q1 		$151K Buy
53,201
+34,881
+190% +$456K ﹤0.01% 1068
2023
Q4 		$270K Buy
18,320
+7,028
+62% +$108K ﹤0.01% 1041
2023
Q3 		$207K Buy
+11,292
New +$239K ﹤0.01% 1052
2023
Q1 		– Sell
-6,298
Closed -$233K – 1142
2022
Q4 		$233K Buy
+6,298
New +$224K ﹤0.01% 1055

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Rafferty Asset Management's AMLX Position: Q1 2026 in Review

Rafferty Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 17,673 shares — an estimated $213K sold.

Rafferty Asset Management first reported a position in AMLX in Q4 2022 and held it in 5 quarters. The position peaked at $270K in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Rafferty Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 17,673 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $213K.
  • Rafferty Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Rafferty Asset Management's Amylyx Pharmaceuticals position peaked at $270K in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.